Annexon is a clinical-stage biopharmaceutical company that develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. Its product candidates include monoclonal antibodies and small molecules that target distinct disease processes. The company's lead candidate, ANX005, is in Phase II/III clinical trials for guillain-barré syndrome and other indications. Annexon was founded in 2011 and is headquartered in Brisbane, California.